US 12,168,660 B2
Derivatives of an FGFR inhibitor
Ming Tao, Maple Glen, PA (US); and Jason Boer, Landenberg, PA (US)
Assigned to Incyte Corporation, Wilmington, DE (US)
Filed by Incyte Corporation, Wilmington, DE (US)
Filed on Jul. 22, 2022, as Appl. No. 17/814,350.
Application 17/814,350 is a continuation of application No. 17/110,875, filed on Dec. 3, 2020, granted, now 11,407,750.
Claims priority of provisional application 62/943,406, filed on Dec. 4, 2019.
Prior Publication US 2022/0411423 A1, Dec. 29, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/5377 (2006.01); A61K 9/00 (2006.01); A61K 31/519 (2006.01); C07D 471/14 (2006.01)
CPC C07D 471/14 (2013.01) [A61K 9/0053 (2013.01)] 19 Claims
 
1. A method of treating cancer in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a compound which is selected from:
3-(2,6-difluoro-3-hydroxy-5-methoxyphenyl)-1-ethyl-8-(morpholinomethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[4,3-d]pyrimidin-2-one; and
3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-4-hydroxy-8-(morpholinomethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[4,3-d]pyrimidin-2-one, or a pharmaceutically acceptable salt thereof.